ArticleScientific reports2025
Comparative diabetes mellitus burden trends across global, Chinese, US, and Indian populations using GBD 2021 database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Risk of Disease Progression of Type 1 Diabetes in First-Degree Relatives of People With Type 1 Diabetes: Design and Rationale of a Prospective, Longitudinal Study in China.Diabetes, obesity & metabolism · 2026Article
- Acute glucose stimulation drives coordinated translational reprogramming in primary pancreatic islets: from global remodeling to fine-tuned insulin synthesis.Frontiers in endocrinology · 2026Article
- Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review.International journal of general medicine · 2026Review
- Chronic Infections and Diabetes in Africa: A Narrative Review of Pathogen-Associated Metabolic Risk.Cureus · 2025Review
- Three decades of CKD due to diabetes mellitus type 2 in China, with projections of disease burden from 2022 to 2036: a systematic analysis for the Global Burden of Disease Study 2021.Clinical kidney journal · 2025Article
- Persistently high and fluctuating trajectories of total and somatic depressive symptoms increase diabetes risk: Two prospective cohort studies.World journal of diabetes · 2025Article
- Interaction of triglyceride glucose index and weight-adjusted waist circumference index in the risk of diabetes: from a national cohort study.BMC endocrine disorders · 2025Article
- Global epidemiological trends and burden of cervical and subcervical spinal cord injuries, 1990-2021: a multidimensional analysis using global burden of disease data.Journal of orthopaedic surgery and research · 2025Article
- Global health burden and inequality patterns of occupational noise exposure from 1990 to 2019.Scientific reports · 2025Article
- A comparison of trends in the incidence of non-alcoholic steatohepatitis-related liver cancer in the BRICS countries from 1990 to 2021, alongside projections for the next 15 years.Frontiers in oncology · 2025Article
- Trends in type 2 diabetes-related deaths and disability-adjusted life years among smoking middle-aged and elderly adults in China, 1990-2021.Tobacco induced diseases · 2025Article
- Diabetes and Menopause: An Intricate Interplay.Journal of mid-life healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diabetic mellitus (DM) poses a significant challenge and stress to global health, comparing the burden of disease in the world's three most populous countries while projecting changes in trends in age-standardized rate (ASR) -deaths and disability adjusted life years (DALYs) up to 2050. Using GBD2021 data, we examined DM trends in China, US, India and globally for 1990-2021, and projected deaths and DALYs for DM (types 1 and 2) for 2022-2050 using Bayesian age-period-cohort (BAPC) model. It was found that the ASR-DALYs and deaths for T1DM are trending downward globally, while those for T2DM are trending upward. In terms of gender differences, the burden of T1DM by gender was insignificant, whereas the burden of disease was significantly higher in men with T2DM than in women. The burden of disease for T1DM peaks around the ages of 40-44 years, while the burden of disease for T2DM peaks at 65-69 years. Population growth and ageing are major factors influencing the disease burden of diabetes. The projection of ASR-deaths and DALYs globally for 2022-2050 showed a decreasing trend in T1DM and an increasing trend in T2DM (especially in China and India). The increasing burden of T2DM disease globally and in three countries by 2050 should be taken seriously.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.